Movatterモバイル変換

[0]ホーム
URL:

Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Prostate Cancer and Prostatic Diseases
  • Original Article
  • Published:

Clinical Research

Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy

Prostate Cancer and Prostatic Diseasesvolume 15, pages75–86 (2012)Cite this article

Abstract

Background:

In the era when various treatment agents for advanced-stage prostate cancer are available, it is important to investigate overall survival for metastatic prostate cancer treated with step-up hormonal treatment as a reference against new treatment regimens, including antitumor agents and/or new hormonal derivatives, and it is desirable to explore pretreatment, biopsy-related and post-treatment prognostic factors to establish tailor-made treatment strategies.

Methods:

Between 1992 and 2002, 94 patients were diagnosed with prostate cancer with distant metastases in our facility. Various pretreatment clinical findings including serum PSA, testosterone, alkaline phosphatase (ALP), digital rectal examination (DRE) and extension of disease score were investigated for predicting outcomes in step-up hormonal treatment. We also investigated the impact of pathological findings including Gleason grading, tumor volume indices, various Gleason grade 5 volume indices in biopsy specimens, and post-treatment PSA nadir following step-up hormonal treatment on overall survival.

Results:

The 3- and 5-year overall survival was 72.4% and 62.5%, respectively. According to univariate analyses, patients with PSA⩽100 ng ml–1, ALP <440 IU l–1, T1c to T3 on DRE, extension of disease (EOD) score 0–3, no Gleason grade 5 cancer in biopsy specimens or less such cancer and good response at any stage of hormonal therapy had significantly better overall survival than did patients with alternative status. A multivariate Cox proportional hazard model revealed that PSA nadir after first-line hormonal treatment, PSA nadir after second-line treatment and Gleason grade 5 volume index were independent prognostic factors.

Conclusions:

Even in very advanced prostate cancer, local pathological indices, a Gleason grade 5 volume index in particular, could differentiate patients with better prognosis from worse prognosis. Step-up hormonal therapy including luteinizing hormone-releasing hormone agonist, estrogen derivatives and steroid hormones may be valuable in patients with metastatic prostate cancer, especially in good responders at any stage of hormonal therapy.

This is a preview of subscription content,access via your institution

Access options

Access through your institution

Subscribe to this journal

Receive 4 print issues and online access

￥40,000 per year

only ￥10,000 per issue

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, Oberaigner Wet al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality.BJU Int 2008;101: 809–816.

    Article CAS  Google Scholar 

  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray Tet al. Cancer statistics, 2008.CA Cancer J Clin 2008;58: 71–96.

    Article  Google Scholar 

  3. Ito K, Yamamoto T, Takechi H, Suzuki K . Impact of exposure rate of PSA-screening on clinical stage of prostate cancer in Japan.J Urol 2006;175 (Suppl): 477–478.

    Article  Google Scholar 

  4. Cancer statistics in Japan 2010. Number of Deaths, by Cancer Site (2008/2009).

  5. Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association.Int J Urol 2005;12: 46–61.

    Article  Google Scholar 

  6. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KNet al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.N Engl J Med 2004;351: 1502–1512.

    Article CAS  Google Scholar 

  7. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin MEet al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.N Engl J Med 2004;351: 1513–1520.

    Article CAS  Google Scholar 

  8. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou Eet al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study.Lancet 2010;375: 1437–1446.

    Article CAS  Google Scholar 

  9. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu Let al. Abiraterone and increased survival in metastatic prostate cancer.N Engl J Med 2011;364: 1995–2005.

    Article CAS  Google Scholar 

  10. Dreicer R, Agus DB, MacVicar GR, MacLean D, Zhang T, Stadler WM . Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant, metastatic prostate cancer: a phase I/II, open-label study.American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). San Francisco, CA, March 5–7, 2010.

    Google Scholar 

  11. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DFet al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.N Engl J Med 2010;363: 411–422.

    Article CAS  Google Scholar 

  12. Antonarakis ES, Eisenberger MA . Expanding treatment options for metastatic prostate cancer.N Engl J Med 2011;364: 2055–2058.

    Article CAS  Google Scholar 

  13. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway Set al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan.Cancer 1988;61: 195–202.

    Article CAS  Google Scholar 

  14. Epstein JI, Allsbrook WC, Amin MB, Egevad LL . The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma.Am J Sur Pathol 2005;29: 1228–1242.

    Article  Google Scholar 

  15. Cooper EH, Armitage TG, Robinson MR, Newling DW, Richards BR, Smith PHet al. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer.Cancer 1990;66 (5 Suppl): 1025–1028.

    Article CAS  Google Scholar 

  16. Imai K, Tomaru Y, Ohnuki T, Yamanaka H, Sakai H, Kanetake Het al. Significance of a new stratification of alkaline phosphatase and extent of disease in patients with prostate carcinoma with bone metastasis.Cancer 1992;69: 2983–2989.

    Article CAS  Google Scholar 

  17. Albertsen PC, Hanley JA, Fine J . 20-year outcomes following conservative management of clinically localized prostate cancer.JAMA 2005;293: 2095–2101.

    Article CAS  Google Scholar 

  18. Cheng L, Koch MO, Juliar BE, Daggy JK, Foster RS, Bihrle Ret al. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy.J Clin Oncol 2005;23: 2911–2917.

    Article  Google Scholar 

  19. Collette L, de Reijke TM, Schröder FH . Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892).Eur Urol 2003;44: 182–189.

    Article  Google Scholar 

  20. Furuya Y, Akakura K, Tobe T, Ichikawa T, Igarashi T, Ito H . Prognostic significance of changes in prostate-specific antigen in patients with metastasis prostate cancer after endocrine treatment.Int Urol Nephrol 2001;32: 659–663.

    Article CAS  Google Scholar 

  21. Kwak C, Jeong SJ, Park MS, Lee E, Lee SE . Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer.J Urol 2002;168: 995–1000.

    Article  Google Scholar 

  22. Benaim EA, Pace CM, Lam PM, Roehrborn CG . Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer.Urology 2002;59: 73–78.

    Article  Google Scholar 

  23. Morote J, Trilla E, Esquena S, Abascal JM, Reventos J . Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer.Int J Cancer 2004;108: 877–881.

    Article CAS  Google Scholar 

  24. Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, Moul JWet al. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.J Clin Oncol 2005;23: 6556–6560.

    Article  Google Scholar 

  25. Robinson D, Sandblom G, Johansson R, Garmo H, Aus G, Hedlund POet al. PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer.Urology 2008;72: 903–907.

    Article  Google Scholar 

  26. Daskivich TJ, Regan MM, Oh WK . Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.Urology 2007;70: 527–531.

    Article  Google Scholar 

  27. Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding Get al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.J Clin Oncol 2009;27: 2450–2456.

    Article  Google Scholar 

  28. Usami M, Akaza H, Arai Y, Hirano Y, Kagawa S, Kanetake Het al. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients.Prostate Cancer Prostatic Dis 2007;10: 194–201.

    Article CAS  Google Scholar 

  29. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson ALet al. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.Urology 1996;47 (1A Suppl): 54–60.

    Article CAS  Google Scholar 

  30. Akaza H, Yamaguchi A, Matsuda T, Igawa M, Kumon H, Soeda Aet al. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients.Jpn J Clin Oncol 2004;34: 20–28.

    Article  Google Scholar 

  31. Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials.Lancet 2000;355: 1491–1498.

    Article  Google Scholar 

  32. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJet al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.N Engl J Med 1998;339: 1036–1042.

    Article CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan

    S Miyamoto, K Ito, M Miyakubo, R Suzuki, T Yamamoto & K Suzuki

  2. Division of Pathology, Geriatrics Research Institute, Maebashi, Japan

    K Suzuki

  3. Institute for Preventive Medicine, Kurosawa Hospital, Takasaki, Japan

    H Yamanaka

Authors
  1. S Miyamoto

    You can also search for this author inPubMed Google Scholar

  2. K Ito

    You can also search for this author inPubMed Google Scholar

  3. M Miyakubo

    You can also search for this author inPubMed Google Scholar

  4. R Suzuki

    You can also search for this author inPubMed Google Scholar

  5. T Yamamoto

    You can also search for this author inPubMed Google Scholar

  6. K Suzuki

    You can also search for this author inPubMed Google Scholar

  7. K Suzuki

    You can also search for this author inPubMed Google Scholar

  8. H Yamanaka

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toK Ito.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

About this article

Cite this article

Miyamoto, S., Ito, K., Miyakubo, M.et al. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.Prostate Cancer Prostatic Dis15, 75–86 (2012). https://doi.org/10.1038/pcan.2011.47

Download citation

Keywords

Access through your institution
Buy or subscribe

Advertisement

Search

Advanced search

Quick links

[8]ページ先頭
©2009-2025 Movatter.jp